Hollow Brook Wealth Management’s Standard BioTools LAB Stock Holding History

Hollow Brook Wealth Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.53M	Sell	5,503,381 -150,000	-3%	-$142K	0.9%	24
2026 Q1	$5.2M	Buy	5,653,381 +100,000	+2%	+$121K	1.33%	21
2025 Q4	$7.11M	Sell	5,553,381 -222,358	-4%	-$299K	1.84%	13
2025 Q3	$7.51M	Buy	5,775,739 +165,428	+3%	+$217K	1.78%	15
2025 Q2	$6.73M	Buy	5,610,311 +56,930	+1%	+$63.1K	1.96%	11
2025 Q1	$6M	Buy	5,553,381 +50,000	+0.9%	+$70.2K	1.76%	16
2024 Q4	$9.63M	Sell	5,503,381 -29,570	-0.5%	-$55.1K	2.96%	6
2024 Q3	$10.7M	Buy	+5,532,951	New	+$10.8M	3.17%	6
2024 Q1	–	Sell	-1,874,405	Closed	-$4.14M	–	86
2023 Q4	$4.14M	Buy	1,874,405 +88,648	+5%	+$189K	1.65%	18
2023 Q3	$5.18M	Buy	+1,785,757	New	+$4.67M	2.16%	13
2023 Q1	–	Sell	-699,611	Closed	-$819K	–	87
2022 Q4	$819K	Buy	+699,611	New	+$861K	0.39%	49

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hollow Brook Wealth Management's LAB Position: Q2 2026 in Review

Hollow Brook Wealth Management reduced its Standard BioTools (LAB) stake by 2.7% in Q2 2026, selling an estimated $142K and leaving 5,503,381 shares worth $4.53M. The position accounts for 0.9% of the portfolio, ranked #24.

Hollow Brook Wealth Management first reported a position in LAB in Q4 2022 and has held it in 11 quarters since. The position peaked at $10.7M in Q3 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Hollow Brook Wealth Management held 5,503,381 shares of Standard BioTools worth $4.53M as of Q2 2026.
Hollow Brook Wealth Management sold 150,000 Standard BioTools shares in Q2 2026, an estimated $142K.
Standard BioTools made up 0.9% of Hollow Brook Wealth Management's portfolio in Q2 2026, its #24 holding.
Hollow Brook Wealth Management first reported a position in Standard BioTools in Q4 2022 and has held it in 11 quarters since.
Hollow Brook Wealth Management's Standard BioTools position peaked at $10.7M in Q3 2024.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Hollow Brook Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.